| Drug General Information |
| Drug ID |
D0B4CA
|
| Former ID |
DNC010636
|
| Drug Name |
NSC-656158
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H10FNO3
|
| Canonical SMILES |
C1OC2=C(O1)C=C3C(=C2)C(=O)C=C(N3)C4=CC=CC=C4F
|
| InChI |
1S/C16H10FNO3/c17-11-4-2-1-3-9(11)12-6-14(19)10-5-15-16(21-8-20-15)7-13(10)18-12/h1-7H,8H2,(H,18,19)
|
| InChIKey |
ZMYDAPJHGNEFGQ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Mitogen-activated protein kinase 10 |
Target Info |
Inhibitor |
[1]
|
|---|
| Amine oxidase [flavin-containing] A |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Superpathway of tryptophan utilization
|
|
Dopamine degradation
|
|
Putrescine degradation III
|
|
Noradrenaline and adrenaline degradation
|
|
Serotonin degradation
|
|
Superpathway of melatonin degradation
|
|
Melatonin degradation II
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
cAMP signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Protein processing in endoplasmic reticulum
|
|
Wnt signaling pathway
|
|
Osteoclast differentiation
|
|
Focal adhesion
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
TNF signaling pathway
|
|
Neurotrophin signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Dopaminergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
Insulin signaling pathway
|
|
GnRH signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Prolactin signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pertussis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Influenza A
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Colorectal cancer
|
|
Pancreatic cancer
|
|
Choline metabolism in cancerhsa00260:Glycine, serine and threonine metabolism
|
|
Arginine and proline metabolism
|
|
Histidine metabolism
|
|
Tyrosine metabolism
|
|
Phenylalanine metabolism
|
|
Tryptophan metabolism
|
|
Drug metabolism - cytochrome P450
|
|
Metabolic pathways
|
|
Serotonergic synapse
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Alcoholism
|
|
NetPath Pathway
|
IL4 Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
Apoptosis signaling pathway
|
|
B cell activation
|
|
EGF receptor signaling pathway
|
|
FAS signaling pathway
|
|
FGF signaling pathway
|
|
Integrin signalling pathway
|
|
Interferon-gamma signaling pathway
|
|
Parkinson disease
|
|
TGF-beta signaling pathway
|
|
Ras Pathway
|
|
CCKR signaling map STP00001:Adrenaline and noradrenaline biosynthesis
|
|
5-Hydroxytryptamine degredation
|
|
Dopamine receptor mediated signaling pathway
|
|
Pathway Interaction Database
|
Noncanonical Wnt signaling pathway
|
|
CD40/CD40L signaling
|
|
FAS (CD95) signaling pathway
|
|
Glucocorticoid receptor regulatory network
|
|
FoxO family signaling
|
|
p75(NTR)-mediated signaling
|
|
ErbB2/ErbB3 signaling events
|
|
PDGFR-beta signaling pathway
|
|
Nephrin/Neph1 signaling in the kidney podocyte
|
|
PathWhiz Pathway
|
Histidine Metabolism
|
|
Tyrosine Metabolism
|
|
Glycine and Serine Metabolism
|
|
Reactome
|
Oxidative Stress Induced Senescence
|
|
FCERI mediated MAPK activation
|
|
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
|
|
Activation of the AP-1 family of transcription factorsR-HSA-181430:Norepinephrine Neurotransmitter Release Cycle
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
DNA Damage Response (only ATM dependent)
|
|
G13 Signaling Pathway
|
|
Insulin Signaling
|
|
Wnt Signaling Pathway
|
|
MAPK Cascade
|
|
Oxidative Stress
|
|
Wnt Signaling Pathway and Pluripotency
|
|
Apoptosis Modulation by HSP70
|
|
MAPK Signaling Pathway
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
Apoptosis
|
|
BDNF signaling pathway
|
|
Integrin-mediated Cell Adhesion
|
|
Regulation of toll-like receptor signaling pathwayWP706:SIDS Susceptibility Pathways
|
|
Biogenic Amine Synthesis
|
|
Dopamine metabolism
|
|
Phase 1 - Functionalization of compounds
|
|
Neurotransmitter Release Cycle
|
|
Neurotransmitter Clearance In The Synaptic Cleft
|
|
Serotonin Transporter Activity
|
| References |
| REF 1 | J Med Chem. 2010 Feb 25;53(4):1616-26.Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent. |
|---|
